In one of the two studies, ALK rearrangement (n = 9) of NSCLC, which was excluded in our study, was included and analyzed, and most patients (50%) took gefitinib (first-generation EGFR-TKI) [23]. Here, ALK is linked to non-small cell lung carcinoma.